Lung distribution of the chemopreventive agent difluoromethylornithine (DFMO) following oral and inhalation delivery

Experimental Lung Research

Volumn 30, Issue 8, 2004, Pages 755-769

  Liao, Xiangmin ^a   Liang, Wei ^a   Wiedmann, Timothy ^a   Wattenberg, Lee ^b   Dahl, Alan ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Aerosol; Chemoprevention; DFMO; Lung cancer; Pharmacokinetics

Indexed keywords

EFLORNITHINE; SOLVENT;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEEDING; HAMSTER; INHALATION; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE LEVEL;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; EFLORNITHINE; FEMALE; LUNG; MICE; MICE, INBRED A;

EID: 8644223251     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.1080/01902140490517836     Document Type: Article

References (17)

1. Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG: Development of inhalational agents for oncologic use. J Clin Oncol. 2001;19:1839-1847.
2. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Galbraith AR, Steele VE, Kelloff GJ: Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis. 2000;21:179-182.
3. Dahl AR, Grossi IM, Houchens DP, Scovell LJ, Placke ME, Imondi AR, Stoner GD, De Luca LM, Wang D, Mulshine JL: Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin Cancer Res. 2000;6:3015-3024.
4. Skubitz KM, Anderson PM: Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anti-Cancer Drugs. 2000;11:555-563.
5. Meyskens FL Jr, Gerner EW: Development of difluoromethylornithine (DFMO) as a chemoprevendon agent. Clin Cancer Res. 1999;5:945-951.
6. Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, Pomplun M, Wilding G: Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. J Natl Cancer Inst. 1993;85:732-737.
7. Simoneau AR, Gerner EW, Phung M, McLaren CE, Meyskens FL Jr: Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial. J Natl Cancer Inst. 2001;93:57-59.
8. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CHJ, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, Boyd NF, Arneson DW, Johnson KA: A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res. 2002;8:3105-3117.
9. Wattenberg LW, Wiedmann TS, Estensen RD: Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. Cancer Res. 2004;64(7):2347-2349.
10. Cohen FL, Ko RJ, Lo ATL, Shields MD, Gilman TM: High-pressure liquid chromatographic analysis of eflornithine in serum. J Pharm Sci. 1989;78:114-116.
11. Guyton AC: Measurement of the respiratory volumes of laboratory animals. Am J Physiol. 1947;150:70-77.
12. Mollmann H, Wagner M, Krishnaswami S, Dimova H, Tang Y, Falcoz C, Daley-Yates PT, Drieg M, Stockmann R, Barth J, Lawlor C, Mollmann AC, Derendorf H, Hochhaus G: Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus™ or Turbohaler™ dry-powder inhalers to healthy subjects. J Clin Pharmacol. 2001;41:1329-1338.
13. Haegele KD, Alken RG, Grove J, Schechter PJ, Koch-Weser J: Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin Pharmacother. 1981;30:210-217.
14. Loiseau PM, Chauffert O, Czok M: Effect of chronic trypanosomiasis on the bioavailability of alpha-difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay. J Chromatogr. A 1995;716:381-388.
15. Grove J, Fozard JR, Mamont PS: Assay of alpha-difluoromethylornithine in body fluids and tissues by automatic amino-acid analysis. J Chromatog. 1981;223:409-416.
16. Nadithe V, Rahamatalla M, Finlay WH, Mercer JR, Samuel J: Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs. J Pharm Sci. 2003;92:1066-1076.
17. Raabe OG, Al-Bayati MA, Teague SV, Rasolt A: Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals. Ann Occup Hyg. 1988;32:53-63.